NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









VectorY Therapeutics

VectorY Therapeutics

Private
AmsterdamHealthcare & Life Scienceshttps://www.vectorytx.com/

Last Round

Series A

Nov 13, 2023

Total Funding Raised

$176M

Company Overview

VectorY Therapeutics is a biotechnology company that develops vectorized antibody therapies for neurodegenerative diseases including ALS, Huntington's, and Parkinson's disease.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

gene therapyadeno-associated virusAAVvectorized antibodiesneurodegenerative diseasesCNS-targeted deliveryAAV capsidsviral vectorsbiotech drug developmentblood-brain barriertherapeutic proteinsbiotech licensinggenetic medicineCNS therapeuticsin vivo gene therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

VectorY Therapeutics Comparables

Compare VectorY Therapeutics with similar companies based on industry and business-model similarity.

VectorY Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Capsida Biotherapeutics
81%
Coave Therapeutics
77%
Voyager Therapeutics
76%

VectorY Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ANov 13, 2023
SeedJun 15, 2021

Key People

Founding team and executive leadership

Jim Scibetta

Chief Executive Officer

Executive Team

Barbara Sanders

Chief Technology Officer

Executive Team

VectorY Therapeutics Investors

Notable investors and investment history

VectorY Therapeutics investors
InvestorRounds
EQT Life SciencesSeries A
ForbionSeries A, Seed
ALS Investment FundSeries A
BioGeneration VenturesSeries A, Seed
Insight PartnersSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 16, 2025

    Developing vectorized antibody therapies with Shape Therapeutics.

  • Dec 16, 2025

    Collaborating with Shape Therapeutics on vectorized antibody therapies for neurodegenerative diseases.

VectorY Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

VectorY Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about VectorY Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersAmsterdam
Employee Range109
Year Founded2020
Last FundingNov 13, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.